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eMethods. Supplemental Methods 
Additional Inclusion and Exclusion Criteria 
Additional inclusion criteria include a reliable informant who personally speaks with or sees that 
subject at least weekly, subject is sufficiently fluent in English to complete all measures, willing 
and able to consent to the protocol and undergo yearly evaluations over 3 years (baseline and at 
years 1, 2, and 3 after baseline), willing and able to undergo neuropsychological testing (at least 
at baseline visit), and no contraindication to MRI imaging. Exclusion criteria include: presence 
of a structural brain lesion (eg, tumor, cortical infarct), presence of another neurologic disorder 
which could impact findings (eg, multiple sclerosis), and unwillingness to return for follow-up 
yearly, undergo neuropsychological testing, MR imaging, presence of amyotrophic lateral 
sclerosis (ALS) at baseline, and no reliable informant. 
 
Clinical Dementia Rating Scale (CDR®) plus Behavioral and Language Domains from the 
National Alzheimer’s Coordinating Center (NACC) FTLD module (CDR® plus NACC 
FTLD) 
The traditional CDR® can be used to generate a total score that represents a weighted average of 
six functional domain scores to categorize each patient as having questionable or mild symptoms 
of neurodegenerative disease (CDR® = 0.5) or clear symptoms of dementia (CDR® = 1, 2, or 3). 
This system is biased toward memory complaints, which are not the presenting symptom in 
many patients with FTLD. To classify cases for this study, we used a scoring algorithm that 
included the traditional CDR® domains and the Behavioral and Language domains, which is 
described in greater detail elsewhere 1. In addition to the global score, we calculated the sum of 
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boxes at each time point; the sum of boxes is an ordinal metric (range: 0 –24) that sums scores 
on each of the eight domains, and has been used as a clinical measure of disease severity in prior 
studies of dementia 2,3. 
 
Image Acquisition 
Participants were scanned at 3 Tesla on MRI scanners from one of three vendors: Philips 
Medical Systems, Siemens, or General Electric Medical Systems. A standard imaging protocol 
was used across all centers, managed and reviewed for quality by a core group at the Mayo 
Clinic, Rochester, MN. Further description of the harmonization and quality control process have 
been described elsewhere4. The current analysis used the T1-weighted images, which were 
acquired as Magnetization Prepared Rapid Gradient Echo (MP-RAGE) images using the 
following parameters: 240x256x256 matrix; about 170 slices; voxel size = 1.05x1.05x1.25 mm3; 
flip angle, TE and TR varied by vendor. 
 
Prior to any preprocessing of images, all T1-weighted scans were visually inspected for quality 
control. Images with excessive motion or other image artifacts were excluded. T1-weighted 
images were bias field corrected using the nonparametric nonuniform intensity normalization 
(N3) algorithm5. Image segmentation was performed with the SPM12 unified segmentation 
framework (Wellcome Trust Center for Neuroimaging, London, UK). 
 
An intra-subject template was created using non-linear diffeomorphic and rigid-body registration 
as proposed by the symmetric diffeomorphic registration for longitudinal MRI framework6. A 
within-subject modulation was applied by multiplying the timepoints’ Jacobians with the intra-
© 2020 Staffaroni AM et al. JAMA Network Open. 
 
subject averaged tissues7. A group template was generated from the within-subject average gray- 
and white-matter tissues and cerebrospinal fluid using Large Deformation Diffeomorphic Metric 
Mapping8. Modulated intra-subject gray and white matter were normalized and smoothed (4mm 
full width half maximum Gaussian kernel) in the group template. Each step of the transformation 
from native space to group template space was carefully inspected for errors. 
 
Bayesian Mixed Effects Model 
In our study, the trajectory is described as a polynomial with degree D of the time, i.e. the age at 
the j-th observation of subject i has a gray matter density (response) in one voxel yij such that 
𝑦 𝜃 𝑡 𝜀  
The model was fitted using a design matrix X(1) built with the age 𝑡 , the subjects’ age at their 
image acquisition time. 𝜃  and 𝜀 are the first level vectors of parameters and noise, 
respectively. Thus, the complete model is written as 𝑦  𝑋 𝜃 𝜀  where X(1) and ε(1) are 
the first level design matrix and noise, respectively. The second level is modeled as 𝜃
𝛸 𝜃 𝜀 , where 𝛸 ,  𝜃 , and 𝜀  are the second level design matrix, parameters, and 
noise, respectively. The second level design matrix consists of the covariates of interest at 
baseline. For this study, we considered age and total intracranial volume (TIV) as covariates. At 
each level, the noise is considered drawn from a centered Gaussian distribution: 𝜀 ~ N(0, Cε(u)), 





To address the main hypothesis that f-FTLD mutations are associated with abnormally high rates 
of volume loss that increase with disease stage, we examined voxel-wise maps of the rates of 
annualized brain volume loss at each disease stage for groups with mutations in each gene and 
compared these with rates in controls. We also fit a three-way interaction model at each voxel: 
rate of atrophy x stage x gene. Significant voxels show that the effect of increasing disease stage 
on volume loss is moderated by gene. Voxel-wise maps depicting regions where rates of volume 
loss were significantly increased in the mutation carrier groups compared with controls were 
produced after correcting for multiple comparisons using FSL’s permutation inference 
framework32 with threshold-free cluster enhancement.33 To understand the cumulative effects of 
decline in volume in each stage, we analyzed cross-sectional volume using the last observation 
for each participant in their disease stage. We compared volumes for each of the genetic groups 
at each of the disease stages with volumes in the control group using the FSL Randomise 
function32 with permutation testing without additional covariates. P values less than 0.05 were 
considered significant and all tests were two-tailed. 
 
To summarize the rates of volume loss in various brain regions, we analyzed data for several 
large ROIs derived by summing ROIs from the Desikan-Killiany atlas34: bilateral frontal, 
temporal, parietal and occipital lobes, and thalamus, and the cerebellum. Thalamic and 
cerebellum ROIs were chosen because of the known involvement of these regions in f-FTLD.3,6 
For each ROI, we extracted each person’s subject-specific slope and report these measurements 
for each group. We do not perform formal statistical tests because statistically significant gene-
by-stage interactions were established for these estimates within the voxelwise Bayesian mixed 
linear effects model and the subject-specific slopes extracted from the Bayesian models are 
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affected by shrinkage towards the mean, resulting in estimated individual trajectories that have 
been shifted closer to parallel with the group trajectory (i.e., important variance has been 
removed from the raw trajectories). 
To examime patterns of change in clinical measures, we created linear mixed effects regression 
models using subject-specific rates of change in CDR®+ NACC FTLD Box Score as the 
dependent variable. The rate of change was extracted from a random slope, random intercept 
linear mixed effects model in which the only predictor was time. Again, due to shrinkage of 
these estimated slopes towards the mean, we present the results without calculating statistical 
significance.  
Image processing and imaging based statistical analyses were conducted using the FMRIB 
Software Library (FSL; fsl.fmrib.ox.ac.uk) and the Statistical Parametric Mapping Software 
package (SPM; www.fil.ion.ucl.ac.uk/spm), and analysis of clinical data were performed using 
Stata version 14.2 (Statacorp).  
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eAppendix. Specific MAPT and GRN Mutations Included in This Study 
 
MAPT: IVS10+16C>T (g.44087784C>T, c.1920+16C>T) 
MAPT: IVS9-10G>T (g.44087666G>A, c.1828-10G>T) 
MAPT: N279K (c.1842T>G, p.N614K ) 
MAPT: P301L (c.1907C>T, p.P636L) 
MAPT: R406W (c.2221C>T, p.R741W) 
MAPT: S305I (c.1919G>T, p.S640I) 
MAPT: S305N (c.1919G>A, p.S640N) 
MAPT: V337M (c.2014G>A, p.V672M) 
 
GRN: A1T (c.A1T, p.Met1Leu) 
GRN: A9D (c.26C>A, p.A9D) 
GRN: I422fs (c.1256_1263dupGAAGCGAG, p.I422Efs*72) 
GRN: IVS3+2T>C (g.42426921T>C, c.264+2T>C) 
GRN: IVS8 (c.836-1G>C p.IVS8-1G>C) 
GRN: E421fs (c.1263_1264insGAAGCGAG,p.E421fs) 
GRN: P512fs (c.1535delC, p.P512Lfs*5) 
GRN: R110X (c.328C>T, p.R110*) 
GRN: R198fs (c.592_593delAG, p.R198Gfs*19) 
GRN: R418X (c.1252C>T, p.R418*) 
GRN: R493X (c.1477C>T, p.R493*) 
GRN: S226fs (c.675_676delCA, p.S226Wfs*28) 
GRN: T52fs (c.154delA, p.T52Hfs*2) 
GRN: W304fs (c.910_911dupTG, p.W304Cfs*58) 





















































eFigure 3. Mean Rates of Volume Loss for Several Regions of Interest 
 CDR® plus NACC FTLD
Controls C9orf72 GRN MAPT
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eTable 1. Demographic information for each subgroup   















Sex (% male) 
Controls - 443.01 (228.82) 2.30 (0.50) 47.17 (12.07) 24 – 76 43 
C9 0 489.12 (310.02) 2.65 (0.75) 43.46 (11.83) 19 – 68 32 
  0.5 403.57 (40.13) 2.40 (0.55) 59.90 (11.39) 50 – 75 42 
  1+ 391.32 (255.23) 2.57 (0.94) 57.66 (9.26) 33 – 67 50 
GRN 0 370.96 (143.02) 2.33 (0.59) 53.22 (15.89) 22 – 71 53 
  0.5 279.75 (172.58) 2.33 (0.52) 54.37 (10.74) 43 – 71 50 
  1+ 258.38 (180.16) 2.78 (1.09) 64.18 (5.67) 51 – 70 8 
MAPT 0 480.64 (186.73) 2.47 (0.61) 39.41 (10.48) 22 – 57 61 
  0.5 415.80 (37.63) 2.25 (0.5) 49.01 (10.11) 36 – 60 78 
  1+ 350.14 (52.10) 2.4 (0.55) 50.87 (11.95) 37 – 67 58 
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eTable 2. Diagnostic composition 
Baseline Clinical Diagnosis (n) Controls CDR 0 CDR 0.5 CDR 1+  
   C9orf72  GRN MAPT C9orf72  GRN MAPT C9orf72  GRN MAPT  
Clinically Normal 56  19  18  19  2       
Alcohol Abuse/Dependence  1          
Alzheimer’s Disease       1 1 2    
ALS     1       
CBS (typical or variant)      1   1   
Behavioral Variant FTD       1 4 1 5  
FTD – Frontal        7 1   
FTD + ALS        1    
MCI – Language         1   
MCI – Mixed or Unspecified      1   1   
MCI – Psychiatric        1    
MCI – Behavior     1 1 2     
MCI – aMCIsd, aMCImd, naMCIsd, 
naMCImd 
    3       
PPA –nonfluent variant         1   
PPA – lopogenic variant         1   
Primary Psychiatric disorder – Mood 4           
Total 60 20 18 19 5 6 4 14 9 5  
                 
 
Note. ALS = Amyotrophic lateral sclerosis; CBS = corticobasal syndrome; FTD = frontotemporal dementia; MCI = mild cognitive 










































  Achieva Biograph mMR Intera TrioTim Discovery MR750 Prisma Fit Skyra Total 
  
       
  
Controls 15 4 18 12 42 37 10 138 
C9 18 0 11 33 17 19 3 101 
GRN 0 2 9 36 20 8 6 81 




eTable 4. Mean and standard deviation (SD) of annualized rate of volume loss 
CDR® + NACC 
FTLD 
Left Frontal Right Frontal 
  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 -170.2 (12.2) -219.5 (74.7) -234.9 (51) -258.5 (98.8) -160.3 (14.6) -271.9 (118.4) -266.9 (80.9) -276.7 (118.7) 
0.5 
 
-392.8 (151.3) -276.9(29.6) -543.9 (300.6) 
 
-309.7 (189.2) -181.8 (89.8) -576.4 (276.2) 
1+ 
 
-285.2 (198.8) -1530.3 (387.6) -2269 (1574.1) 
 
-250.8 (144.5) -1169.2 (555) -2052.8 (2005.7) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 -77.1 (13.1) -128.9 (66.1) -108.7 (17.7) -231 (47.4) -72.5 (16.8) -104.9 (42.8) -108.8 (25.5) -149.6 (35.6) 
0.5 
 
-137.8 (14.6) -126.8 (35.2) -381 (207.9) 
 
-42.9 (27.4) -101.2 (17.2) -315.4 (200.8) 
1+ 
 
-76.8 (43.6) -867.1 (308.4) -1484.6 (1024.8) 
 
-64.3 (46.3) -433.3 (119.2) -1163.9 (882.4) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 -104.9 (13.7) -165.4 (104.7) -140.3 (11.9) -139.1 (26.5) -102.2 (16) -183.8 (157.1) -181.5 (17.2) -133.7 (40.9) 
0.5 
 
-224 (88.9) -154.2 (70.9) -303 (151.2) 
 
-84.2 (91.2) -119.6 (34.5) -330.7 (123.2) 
1+ 
 
-122.3 (156.8) -896.4 (217) -943.7 (650.6) 
 
-123.6 (160) -483.9 (108.2) -729.5 (507.1) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 -27.9 (8.6) -57.3 (26.3) -36 (3.9) -38.3 (10) -31.4 (7.1) -52.3 (14.4) -38.4 (5.2) -37.5 (8.7) 
0.5 
 
-28 (30.1) -49.1 (14.5) -110.2 (68.4) 
 
14.8 (11.7) -38.5 (36.1) -98.7 (59.6) 
1+ 
 
-3.6 (29.8) -56.5 (43.6) -82 (71.2) 
 
-6.3 (38.2) -55.7 (30) -38.1 (88.4) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 -10.5 (1.5) -11 (4.8) -13.4 (1.5) -12.8 (12.9) -76.2 (25.4) -80.3 (28.4) -74.4 (23.3) -176.4 (21.3) 
0.5 
 
-31.3 (9.9) -27.5 (3.9) -77.5 (49.9) 
 
-106.8 (184) -53.6 (123.4) -503.1 (736.8) 
1+ 
 
-4.6 (9.7) -45.1 (21.7) -9.1 (71.8) 
 
-79.5 (88.5) -493.8 (50.8) -652 (413.1) 
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CDR® + NACC 
FTLD 
FTLD-CDR SB 
   
  
  Controls C9orf72 GRN MAPT 




0.1 (.01) 0.1 (.01) 0.1 (.01) 




0.4 (.1) 0.3 (.2) 0.3 (.1) 
   
  
1+   1.5 (.3) 1.4 (.5) 2.2 (1.0)         
 
Note. Coefficients represent the estimated, yearly rate of atrophy (mm3) 
Means and standard deviations were calculated from shrunk estimates derived from a linear mixed effects models 
Because these estimates are shrunk towards the group mean, they include bias and should be interpreted with caution 
Formal statistical tests were not performed due to this bias, but the means and SDs still provide important information about the 























Note. Descriptive statistics are presented for each ROI in units of mm3.  
The last observation of each individual was included in these estimates 
Carriers of the C9orf72 repeat expansion show atrophy compared to controls at a similar level as carriers of GRN and MAPT mutation 
 
eTable 5. Cross-sectional volume by region of interest          
CDR® + NACC FTLD Left Frontal   Right Frontal 
  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 16550.3 (789.9) 16204 (807.6) 16118.9 (910.7) 16640 (1014.8) 16538.8 (809) 16266.8 (791.2) 16055.3 (910) 16547 (1070.6) 
0.5 
 
15521.5 (540) 15684.8 (1028.6) 16016.9 (1397.9) 
 
15544.6 (591.9) 15744.1 (849) 15954 (1242.2) 
1+ 
 
14154 (1298.6) 13440.5 (2042) 12683.4 (2344.7) 
 
14011.9 (1484.6) 13678.9 (2447.5) 13234.7 (2014.6) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 10962.8 (445.2) 10727.4 (400.3) 10689.6 (533.8) 10885.7 (470.8) 10555.3 (394.8) 10376.8 (317.2) 10348.1 (484.7) 10509.6 (385.6) 
0.5 
 
10476.3 (353.8) 10480.2 (577.5) 10259.7 (802.1) 
 
10176.5 (230.5) 10234.7 (452) 10000.4 (531.7) 
1+ 
 
9563.2 (788.4) 9154.6 (1037.5) 8651.7 (1090.2) 
 
9335.9 (734.2) 9270.8 (1530.2) 8627.6 (1236.9) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 9643.9 (532.7) 9322.9 (562.7) 9348.8 (640.9) 9723.9 (653.5) 10004.4 (543.1) 9588 (548.7) 9644.5 (698.1) 10060.8 (610.1) 
0.5 
 
9108.8 (427.4) 8975.5 (781.6) 9004.5 (906.1) 
 
9396.4 (392) 9291.3 (782.7) 9422.7 (732.7) 
1+ 
 
8048.6 (622.3) 7520.5 (1212.8) 8434.9 (715.5) 
 
8283.2 (724.6) 8121.4 (1550.8) 8812.1 (514.9) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 3741.3 (191.9) 3622.8 (185.6) 3636.5 (222.5) 3752.3 (224.2) 3963.8 (172.4) 3822.7 (197.9) 3852.5 (225) 3979.2 (206.5) 
0.5 
 
3508.6 (124) 3493.6 (327.6) 3466.8 (411.6) 
 
3755.2 (82.9) 3710.4 (323.9) 3702.2 (355.3) 
1+ 
 
3126.9 (256.4) 3097.7 (458.3) 3432 (190) 
 
3365 (263.6) 3415 (554.6) 3731.6 (190.6) 
  







  Controls C9orf72 GRN MAPT Controls C9orf72 GRN MAPT 
0 1628.1 (71.9) 1578.9 (62.4) 1571.4 (105.1) 1630.5 (83) 24936.1 (788.6) 24699 (438.1) 24674 (732.2) 24962.4 (763.4) 
0.5 
 
1572.1 (50.7) 1553.7 (97) 1593.1 (60.3) 
 
24312.1 (436.2) 24244.9 (795.2) 24351.7 (1260) 
1+   1395.1 (131.7) 1424.5 (199) 1413.8 (93)   23632.5 (661.6) 23427.9 (1070.5) 24076.1 (537.6) 
